Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 4/20 | 0.60 |
| ▸ | CTSL | P07711 | 4/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27934345 | 0.91 | MAOB (0.57) | CTSVCTSLMAOBALDH1A1HPGD | |
| SCHEMBL7282913 | 0.90 | MAOB (0.68) | MAOBL3MBTL1 | |
| SCHEMBL344833 | 0.89 | FOLH1 (0.68) | CTSVCTSLMAOBFOLH1NR4A2 | |
| SCHEMBL9366548 | 0.89 | MAOB (0.52) | CTSVCTSLMAOBALDH1A1HPGD | |
| SCHEMBL29717104 | 0.89 | MAOB (0.55) | CTSVCTSLMAOBALDH1A1HPGD | |
| SCHEMBL711327 | 0.89 | MAOB (0.55) | CTSVCTSLMAOBALDH1A1HPGD | |
| SCHEMBL15709261 | 0.89 | PARP15 (0.60) | MAOBALDH1A1L3MBTL1PARP15 | |
| SCHEMBL1647498 | 0.88 | FOLH1 (0.63) | CTSVCTSLMAOBFOLH1KDM4E | |
| SCHEMBL1448026 | 0.88 | MAOB (0.61) | CTSVCTSLMAOBNR4A2KDM4E | |
| SCHEMBL10468446 | 0.87 | FOLH1 (0.58) | CTSVCTSLMAOBFOLH1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278940-B2 | Cyclic amines as bromodomain inhibitors | ZENITH EPIGENETICS CORP. (CA) | 2016-03-08 | — | — | US | disclosed |
| US-9278940-B2 | Cyclic amines as bromodomain inhibitors | ZENITH EPIGENETICS CORP. (CA) | 2016-03-08 | — | — | US | disclosed |
| US-20150344442-A1 | CYCLIC AMINES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2015-12-03 | — | — | US | disclosed |
| US-20150344442-A1 | CYCLIC AMINES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2015-12-03 | — | — | US | disclosed |
| US-9073878-B2 | Cyclic amines as bromodomain inhibitors | ZENITH EPIGENETICS CORP. (CA) | 2015-07-07 | — | — | US | disclosed |
| US-9073878-B2 | Cyclic amines as bromodomain inhibitors | ZENITH EPIGENETICS CORP. (CA) | 2015-07-07 | — | — | US | disclosed |
| US-20140142102-A1 | CYCLIC AMINES AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2014-05-22 | — | — | US | disclosed |
| US-20140142102-A1 | CYCLIC AMINES AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2014-05-22 | — | — | US | disclosed |
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| EP-1940837-B1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
| EP-1940837-A2 | IMIDAZOPYRIDINE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | CTSV 2625/4885CTSL 1247/4885MAOB 1046/4885 |
| US-20140142102-A1 | CYCLIC AMINES AS BROMODOMAIN INHIBITORS | BRDT, BRD4, BRD3 | CTSV 4383/4885CTSL 4586/4885MAOB 770/4885 |
| US-20150344442-A1 | CYCLIC AMINES AS BROMODOMAIN INHIBITORS | BRDT, BRD4, BRD3 | CTSV 4383/4885CTSL 4586/4885MAOB 770/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | CTSV 1562/4885CTSL 1613/4885MAOB 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.